Immunocore to present at upcoming investor conferences
Immunocore Holdings plc (Nasdaq: IMCR), a commercial-stage biotechnology company focused on developing immunomodulating medicines for cancer, infectious diseases, and autoimmune diseases, has announced its participation in three major investor conferences in March 2025.
The company will be present at:
- The TD Cowen 45th Annual Healthcare Conference with a presentation on Tuesday, March 4, 2025, at 3:10 p.m. EST
- The Barclays 27th Annual Global Healthcare Conference for a fireside chat on Tuesday, March 11, 2025, at 3:00 p.m. EST
- The Jefferies Biotech on the Beach Summit for one-on-one and small group meetings on Wednesday, March 12, 2025
Interested parties can access live webcasts of the presentations through the 'Events & Presentations' section under 'Events' in the 'Investors' area of Immunocore's website. Replay options will be available for a time after the events.
Immunocore Holdings plc (Nasdaq: IMCR), una società biotecnologica in fase commerciale focalizzata sullo sviluppo di medicinali immunomodulanti per il cancro, le malattie infettive e le malattie autoimmuni, ha annunciato la sua partecipazione a tre importanti conferenze per investitori a marzo 2025.
La società sarà presente a:
- La 45ª Conferenza Annuale sulla Salute di TD Cowen con una presentazione martedì 4 marzo 2025, alle 15:10 EST
- La 27ª Conferenza Annuale Globale sulla Salute di Barclays per una chiacchierata informale martedì 11 marzo 2025, alle 15:00 EST
- Il Summit Jefferies Biotech on the Beach per incontri individuali e di piccoli gruppi mercoledì 12 marzo 2025
Le parti interessate possono accedere alle dirette delle presentazioni attraverso la sezione 'Eventi & Presentazioni' sotto 'Eventi' nell'area 'Investitori' del sito web di Immunocore. Saranno disponibili opzioni di replay per un periodo dopo gli eventi.
Immunocore Holdings plc (Nasdaq: IMCR), una empresa biotecnológica en etapa comercial centrada en el desarrollo de medicamentos inmunomoduladores para el cáncer, enfermedades infecciosas y enfermedades autoinmunes, ha anunciado su participación en tres importantes conferencias para inversores en marzo de 2025.
La empresa estará presente en:
- La 45ª Conferencia Anual de Salud de TD Cowen con una presentación el martes 4 de marzo de 2025, a las 3:10 p.m. EST
- La 27ª Conferencia Global Anual de Salud de Barclays para una charla informal el martes 11 de marzo de 2025, a las 3:00 p.m. EST
- La Cumbre Jefferies Biotech on the Beach para reuniones uno a uno y en grupos pequeños el miércoles 12 de marzo de 2025
Las partes interesadas pueden acceder a las transmisiones en vivo de las presentaciones a través de la sección 'Eventos y Presentaciones' bajo 'Eventos' en el área de 'Inversores' del sitio web de Immunocore. Las opciones de repetición estarán disponibles por un tiempo después de los eventos.
Immunocore Holdings plc (Nasdaq: IMCR)는 암, 감염병 및 자가면역 질환을 위한 면역 조절 약물을 개발하는 데 집중하는 상업 단계의 생명공학 회사로, 2025년 3월에 열리는 세 가지 주요 투자자 회의에 참여한다고 발표했습니다.
회사는 다음과 같은 회의에 참석할 예정입니다:
- TD Cowen 제45회 연례 헬스케어 회의에서 2025년 3월 4일 화요일 오후 3시 10분 EST에 발표합니다.
- 바클레이스 제27회 글로벌 헬스케어 회의에서 2025년 3월 11일 화요일 오후 3시 EST에 대화형 세션을 진행합니다.
- 제퍼리스 비오텍 온 더 비치 서밋에서 2025년 3월 12일 수요일에 일대일 및 소그룹 미팅을 진행합니다.
관심 있는 분들은 Immunocore 웹사이트의 '투자자' 영역 내 '이벤트' 섹션에서 '이벤트 및 발표'를 통해 발표의 라이브 웹캐스트에 접속할 수 있습니다. 이벤트 후 일정 기간 동안 재생 옵션이 제공됩니다.
Immunocore Holdings plc (Nasdaq: IMCR), une entreprise de biotechnologie en phase commerciale axée sur le développement de médicaments immunomodulateurs pour le cancer, les maladies infectieuses et les maladies auto-immunes, a annoncé sa participation à trois grandes conférences pour investisseurs en mars 2025.
L'entreprise sera présente à :
- La 45e Conférence Annuelle sur la Santé de TD Cowen avec une présentation le mardi 4 mars 2025, à 15h10 EST
- La 27e Conférence Annuelle Mondiale sur la Santé de Barclays pour une discussion informelle le mardi 11 mars 2025, à 15h00 EST
- Le Sommet Jefferies Biotech on the Beach pour des réunions individuelles et en petits groupes le mercredi 12 mars 2025
Les parties intéressées peuvent accéder aux webcasts en direct des présentations via la section 'Événements & Présentations' sous 'Événements' dans la zone 'Investisseurs' du site Web d'Immunocore. Des options de rediffusion seront disponibles pendant un certain temps après les événements.
Immunocore Holdings plc (Nasdaq: IMCR), ein biopharmazeutisches Unternehmen in der kommerziellen Phase, das sich auf die Entwicklung von immunmodulierenden Medikamenten für Krebs, Infektionskrankheiten und Autoimmunerkrankungen konzentriert, hat seine Teilnahme an drei wichtigen Investorenkonferenzen im März 2025 bekannt gegeben.
Das Unternehmen wird an folgenden Veranstaltungen teilnehmen:
- Der 45. jährlichen Gesundheitskonferenz von TD Cowen mit einer Präsentation am Dienstag, den 4. März 2025, um 15:10 Uhr EST
- Der 27. jährlichen globalen Gesundheitskonferenz von Barclays für ein informelles Gespräch am Dienstag, den 11. März 2025, um 15:00 Uhr EST
- Dem Jefferies Biotech on the Beach Summit für Einzel- und Kleingruppengespräche am Mittwoch, den 12. März 2025
Interessierte Parteien können über den Bereich 'Ereignisse & Präsentationen' unter 'Ereignisse' im 'Investoren'-Bereich der Immunocore-Website auf die Live-Webcasts der Präsentationen zugreifen. Replay-Optionen werden für eine Zeit nach den Veranstaltungen verfügbar sein.
- None.
- None.
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 03 March 2025) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that management will participate in the following investor conferences in March.
TD Cowen 45th Annual Healthcare Conference
Presentation: Tuesday, March 4, 2025, at 3:10 p.m. EST
Barclays 27th Annual Global Healthcare Conference
Fireside Chat: Tuesday, March 11, 2025, at 3:00 p.m. EST
Jefferies Biotech on the Beach Summit
1x1 and small group meetings: Wednesday, March 12, 2025
Where relevant, the presentations will be webcast live and can be accessed by visiting ‘Events & Presentations’, under ‘Events’, via the ‘Investors’ section of Immunocore’s website at www.immunocore.com. Following the event, a replay of the presentations will be made available for a limited time.
About Immunocore
Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, autoimmune, and infectious disease. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. The Company’s most advanced oncology TCR therapeutic, KIMMTRAK has been approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia, and the United Kingdom.
Contact Information
Immunocore
Sébastien Desprez, Head of Communications
T: +44 (0) 7458030732
E: sebastien.desprez@immunocore.com
Follow on Twitter: @Immunocore
Investor Relations
Clayton Robertson, Head of Investor Relations
T: +1 (215) 384-4781
E: ir@immunocore.com
FAQ
What investor conferences will IMCR attend in March 2025?
When is Immunocore's presentation at the TD Cowen Healthcare Conference?
How can investors access Immunocore's conference presentations?
What type of meetings will IMCR hold at the Jefferies Biotech Summit?
What therapeutic areas does Immunocore focus on?
